Slow Receptor Dissociation Kinetics Differentiate Macitentan from Other Endothelin Receptor Antagonists in Pulmonary Arterial Smooth Muscle Cells

Two endothelin receptor antagonists (ERAs), bosentan and ambrisentan, are currently approved for the treatment of pulmonary arterial hypertension (PAH), a devastating disease involving an activated endothelin system and aberrant contraction and proliferation of pulmonary arterial smooth muscle cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatfield, John, Mueller Grandjean, Celia, Sasse, Thomas, Clozel, Martine, Nayler, Oliver
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471877/
https://www.ncbi.nlm.nih.gov/pubmed/23077657
http://dx.doi.org/10.1371/journal.pone.0047662

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3471877/
https://www.ncbi.nlm.nih.gov/pubmed/23077657
http://dx.doi.org/10.1371/journal.pone.0047662

Ejemplares similares